# Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

> **NCT04375527** · PHASE2 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC V8
- Clinical Stage IV Cutaneous Melanoma AJCC V8
- Locally Advanced Cutaneous Melanoma
- Metastatic Cutaneous Melanoma
- Pathologic Stage III Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC V8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
- Pathologic Stage IIID Cutaneous Melanoma AJCC V8
- Pathologic Stage IV Cutaneous Melanoma AJCC V8
- Unresectable Cutaneous Melanoma

## Interventions

- **DRUG:** Binimetinib
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04375527
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-03
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** poor enrollment
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375527, "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04375527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*